Valeo Pharma Inc. provided earnings guidance for the year 2023. The company expects revenues to continue to grow this year with a target revenue base of $60-plus million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.105 CAD | +5.00% | +10.53% | -41.67% |
04-25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
03-22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.67% | 7.25M | |
+31.89% | 694B | |
+29.31% | 593B | |
-1.71% | 371B | |
+19.62% | 331B | |
+6.74% | 290B | |
+14.26% | 239B | |
-3.15% | 209B | |
+10.03% | 209B | |
+8.21% | 169B |
- Stock Market
- Equities
- VPH Stock
- News Valeo Pharma Inc.
- Valeo Pharma Inc. Provides Earnings Guidance for the Year 2023